Blog
Experienced biopharma leader joins Pearl IRB
Pearl IRB announces the hiring of Mark Slisz as a Senior Advisor serving biopharmaceutical, medical device, and diagnostic life science companies. Slisz brings over 35 years of experience in the pharmaceutical industry to Pearl Pathways. His experience...
Making sense of review board jargon: single, central, institutional, and independent IRB
Note: Pearl IRB updated this blog on August 9, 2021, and we will continue to update this in the future as necessary. Formal review procedures for human subject studies were established in reaction to unethical research practices in the 20th century. The Code of...
NIH accelerating the use of genomics in clinical care
The National Institutes of Health (NIH) is awarding $18.9 million towards research aiming to accelerate the use of genome sequencing in clinical care. The new awards will verify that the genomic medicine can be applied to all individuals and groups...
Ethics of an NIH blood transfusion study under scrutiny
According to MedPage Today, Public Citizen is calling for the immediate suspension of a large National Institutes of Health (NIH) sponsored trial comparing blood transfusion strategies after heart attacks. The consumer advocacy group said that the...
Pearl IRB becomes a SMART IRB participating institution
Pearl IRB is pleased to announce that we have joined SMART IRB, a platform to ease common challenges and burdens associated with initiating multisite research. SMART IRB is a collaborative initiative supported by the National Center for Advancing...